This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

imatinib (Glivec®)

Reference No. 1653

Publication date:

Last review date:

Appraisal information

imatinib (Glivec®) 100 mg film-coated tablet
imatinib (Glivec®) 400 mg film-coated tablet

Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 14/05/2014
AWMSG meeting date: 11/06/2014
Submission Type: Full Submission
Status: Superseded
Advice No: 1414
Ratification by Welsh Government: 24/07/2014

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA326) NICE GUIDANCE ISSUED NOVEMBER 2014 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Imatinib (Glivec®) is recommended for restricted use within NHS Wales. Imatinib (Glivec®) should be restricted for use in the following subpopulation within its licensed indication for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of KIT (CD117)-positive gastrointestinal stromal tumours. Patients who have low or very low risk of recurrence should not receive adjuvant treatment. Imatinib (Glivec®) should be restricted for use in patients who are considered to be at high risk of relapse according to the Miettinen criteria. Imatinib (Glivec®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary